Small organometallic compounds as antibacterial agents by Patra, Malay et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Small organometallic compounds as antibacterial agents
Patra, Malay; Gasser, Gilles; Metzler-Nolte, Nils
Abstract: The emergence of bacterial resistance to commercial antibiotics is an issue of global impor-
tance. During the last two decades, the number of antibacterial agents that have been discovered and
introduced into the market has steadily declined and failed to meet the challenges posed by rapidly
increasing resistance of the pathogens against common antibacterial drugs. The development of new
classes of compounds to control the virulence of the pathogens is therefore urgently required. This per-
spective describes the historical development in brief and recent advances on the preparation of small
organometallic compounds as new classes of antibacterial agents with potential for clinical development.
DOI: 10.1039/c2dt12460b
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-69312
Accepted Version
Originally published at:
Patra, Malay; Gasser, Gilles; Metzler-Nolte, Nils (2012). Small organometallic compounds as antibacte-
rial agents. Dalton Transactions, 41:6350-6358. DOI: 10.1039/c2dt12460b
 1
 
Small Organometallic Compounds as Antibacterial Agents 
Malay Patra,†,# Gilles Gasser,#,* and Nils Metzler-Nolte†,* 
† Lehrstuhl für Anorganische Chemie I, Fakultät für Chemie und Biochemie, Ruhr-Universität 
Bochum, Gebäude NC 3 Nord, Universitätsstrasse 150, D-44801 Bochum, Germany, Fax: +49 234 321 
4378, Email: nils.metzler-nolte@rub.de, WWW: www.chemie.rub.de/ac1;  
# Institute of Inorganic Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, 
Switzerland, Fax: +41 44 635 68 03, Email: gilles.gasser@aci.uzh.ch, WWW: www.gassergroup.com  
 
 
Keywords: Antibacterial Agents, Antibiotic Resistance, Bioorganometallic Chemistry, Medicinal 
Inorganic Chemistry, Medicinal Organometallic Chemistry, Metal-based Drugs 
 2
ABSTRACT.  
The emergence of bacterial resistance to commercial antibiotics is an issue of global importance. 
During the last two decades, the number of antibacterial agents that have been discovered and 
introduced into the market has steadily declined and failed to meet the challenges posed by rapidly 
increasing resistance of the pathogens against common antibacterial drugs. The development of new 
classes of compounds to control the virulence of the pathogens is therefore urgently required. This 
perspective describes the historical development in brief and recent advances on the preparation of 
small organometallic compounds as new classes of antibacterial agents with potential for clinical 
development. 
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Introduction.  
The modern age of antimicrobial research is believed to have begun in 1928 with the accidental 
discovery of penicillin by Alexander Fleming.1 However, first Penicillin-resistant S. aureus strains 
were already reported soon after the use of penicillin in the 1940s.2 This was a warning to the 
community that misuse of antibiotics could lead to resistance development in bacteria. Methicillin, a β-
lactamase resistant penicillin class of antibiotic, was introduced in 1959, but S. aureus rapidly acquired 
resistance, leading to the emergence of Methicillin-resistant S. aureus (MRSA).3, 4 MRSAs posed 
further difficulties by developing resistance against other classes of antibiotics such as gentamycin, 
erythromycin and neomycin as well. The Gentamycin-resistant MRSA (GR-MRSA) was isolated in 
Australia, USA and Europe in the early 1980’s. In the 1990’s, resistance to ciprofloxacin, a 
fluoroquinolone antibiotic used for the treatment of MRSA infection, was also reported.5 Vancomycin, 
a glycopeptide antimicrobial was used for the last two decades to control the virulence of such multi-
resistant MRSAs. Due to the selective pressure of Vancomycin, reduced susceptibility of S. aureus 
towards this antibiotic emerged during this time. In 2002, Vancomycin-resistant S. aureus (VRSA) was 
first isolated in Michigan and Pennsylvania.6, 7 It is evident that the development of antibiotic resistance 
to conventional and purely organic antibiotics is a routine process. Bacteria can develop resistance 
amazingly fast and, in some cases, resistance was already noticed even before the compound was 
commercially available for human use!8 This is probably the reason why quite a number of 
pharmaceutical companies are currently reluctant to invest money into the development of new 
antibiotics.  
Antimicrobial resistance is a serious issue not only in patient care facilities such as hospitals where 
antibiotics are heavily used but also in surrounding communities because of rapid sharing of resistant 
genes between bacteria.9 As a result, difficult-to-treat forms of infectious diseases caused by 
pathogenic superbugs are emerging. Most feared are those strains which are no longer treatable by any 
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available antibiotics. As shown in Figure 1, commercialization of antibiotics has decreased steadily 
after the 1980s. On the other hand, the significant occurrence of MRSA has begun mainly after 1995. 
During the last two decades, the number of antibacterial agents that have been discovered and 
introduced into the market has steadily declined and failed to meet the challenges posed by multidrug 
resistant pathogens.10-12 Therefore, there is an urge to search for new classes of antimicrobial 
compounds with completely new modes of action to control the virulence of multidrug-resistant 
pathogens. 
 
 
Figure 1. a) Decade wise approval of new antibiotics and b) prevalence of MRSA.13  
 
Organometallic derivatization of an existing drug is an attractive approach to overcome the resistance 
issue. This strategy could indeed offer a metal-specific mode of action which is not available for the 
purely organic parent drug molecule. In this sense, one of the leading examples in medicinal 
organometallic chemistry is the antimalarial candidate ferroquine.14-16 This ferrocenyl derivative of 
chloroquine reveals activity similar to that of the parent compound against a chloroquine-sensitive P. 
falciparum strain (HB3 5CQS), while comparison of activity of ferroquine and chloroquine against 
chloroquine-resistant P. falciparum (Dd2) showed that the former is ten times more active than the 
latter.14, 15  In some cases, it was believed that the activity of a metal-derivatized-drug could be the sum 
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of the original activity and the inherent toxicity of the abiotic metal. For example, in the case of the 
arsenic-containing drug Salvarsan (see below), the general toxicity of As contributes to the overall 
antibacterial activity of the compound.13 It is difficult for microorganisms to develop resistance against 
drugs with multiple targets, particularly, if resistance is associated with the target modification. Indeed, 
it has already been shown that the ability of bacteria to develop resistance against silver-based 
antimicrobials is limited, therefore enabling such antibiotics to survive long on the market.17, 18    
There are significant advances in the development of organometallic-containing, and more generally, 
metal-containing anticancer and anti-malarial compounds.19-24 In contrast, very little attention has been 
paid to the development of organometallic antibacterial drugs. Hence, explorations of metal-based 
antibacterial compounds are desirable, since the metal-specific mode of action of the metallo-drug may 
provide opportunities to overcome the development of antibiotic resistance. In this perspective, we 
present recent advances on the development of such compounds. We will focus our attention only on 
organometallic compounds, i.e. ones that possess at least one direct metal-carbon bond (consequently, 
classical coordination compounds are not considered herein). Furthermore, due to space restriction, we 
have decided to review only small organometallic compounds, thereby excluding antibacterial 
organometallic-containing peptide conjugates21, 25, 26 or nanoparticles.27-30 An excellent perspective 
article describing the synthesis and antimicrobial activity of nanoparticle-encapsulated silver-carbene 
complexes has been recently published by Youngs et al.17   
Organoarsenical Complexes as Antimicrobial Agents. 
As surprising as it can be, arsenic compounds are still currently being employed in medicinal 
chemistry, as evidenced by the relatively recent approval (in 2003) by the FDA of As2O3 (sold under 
the trade name Trisenox®) for the treatment of patients with relapsed acute myeloid leukemia.31, 32 But, 
in the field of medicinal organometallic chemistry, Atoxyl (Trypoxyl®, Figure 2) was the first 
compound to be clinically used, first against trypanosomiasis (often called sleeping sickness), and then 
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syphilis at the beginning of the 20th century, and this despite very serious side-effects.32 A review 
article describes the structure, reactivity and biological activity of arsenic compounds was published by 
Sadler et al. few years ago.33 An excellent book chapter on organoarsenical drugs has recently been 
published by Gibaud and Jaouen.32 Readers of this perspective are encouraged to refer to the review 
and the book chapter for further information on this subject. Nonetheless, the golden age of 
organoarsenical complexes as antimicrobial agents and, more generally in the field of medicinal 
organometallic chemistry, has been the discovery by the Nobel laureate Paul Ehrlich34 of Salvarsan® 
(1910) and later of the more soluble but slightly less effective Neosalvarsan® (1912) for the treatment 
of syphilis (Figure 2). Until the advent of these drugs in the early 1900s, syphilis was a major, and 
often deadly, infection which was treated with mercury and potassium iodide.32 And despite their 
severe side-effects, these compounds were only supplanted by penicillin in the 1940s. Interestingly, 
while it was clear that the formulation of Salvarsan with an As=As double bond was only a formal one, 
the “real” structure of Salvarsan® as a mixture of three- and five-membered cyclic compounds was 
only discovered in 2005 by mass spectrometry (Figure 2).35 It is also interesting to note that an arseno-
bismuth compound Bimarsen® (Figure 2) was also used for the treatment of syphilis due its low 
toxicity, tonic effect and ease of administration as well as its ability to be relapsed more frequently in 
the central nervous system than other arsenic compounds.32 This allows neurosyphilis to be treated.32 In 
more recent times, other infections caused by Entamoeba histolytica (Amebiasis) or Trichomonas 
Vaginalis as well as Vincent’s Angina were treated with organoarsenical complexes such as those 
presented in Figure 2.32 A few of these compounds were withdrawn from the market only in the 1990s. 
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Figure 2. Structures of some relevant arsenic-based drugs (non-exhaustive list!). See the text for a 
discussion of formal structures of Salvarsan and its derivatives (with As=As bonds) vs. experimental 
ones. 
 
Organometallic Derivatives of Penicilin and Quinolone Antibacterials.  
In a more rational drug design approach, Epton, Marr and coworkers published a series of papers in 
the 1970s describing the synthesis of ferrocene analogues of well-established antibacterial drugs such 
as penicillins and cephalosporins.36-39  
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 In their work, benzene rings in prominent positions were replaced by ferrocene. In particular, 
antibacterial drugs that inhibit the cell wall biosynthesis from the penicillin and cephalosphorin 
families were chosen. Figure 3 shows selected examples from their work. For compound 2 with R1 = 
R2 = H, the antibacterial activity was tested and found to be comparable with the parent benzyl-
penicillin. Activity in this series decreased with increasing number of R = Me. None of the ferrocenyl 
derivatives of penicillin reached the potency of the organic analogues. However, no MIC values or 
more detailed information was given, and it was never investigated whether the metallocene analogues 
do actually follow the same mechanism of action as the parent compounds. It hence remains unclear 
whether they could help to overcome resistance against penicillin-resistant microbes in a manner 
similar to the anti-malarial compound ferroquine (vide infra). 
More recently, two papers report on organometallic derivatives of quinolone antibiotics. Quinolones 
are exerting their bacteriocidal activity by inhibiting the topoisomerase II enzyme, which unwinds 
DNA, and thus interfere with DNA replication. Norfloxacin (nor) reacts with W(CO)6 in 1M NaOH in 
a Pyrex tube, yielding a 1:1 complex with the formula (nor)W(CO)3(H2O), of which a single crystal X-
ray structure could be obtained.40 Analogously, a suitable Ru precursor reacts with ofloxacin (oflo) and 
NaOH in methanol to give the complex (6-p-cymene)RuCl(oflo).41 In both compounds, the quinolone 
is bidentately coordinated to the metal through the ring carbonyl and one of the carboxylic oxygen 
atoms (Figure 4). Both compounds exhibit good antibacterial activity and in addition, a direct 
interaction of the Ru complex with double-stranded DNA was proven. 
Finally, a cyanoferrate(II) complex of isoniazid (ison), [Fe(CN)5(ison)]3-, inhibits both the wild-type 
and an isoniazid-resistant I21V mutant of enoyl reductase enzymes from Mycobacterium 
tuberculosis.42 In vitro, this complex has about the same activity as isoniazid itself against wild type M. 
tuberculosis, the bacterium that causes tuberculosis. 
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Figure 3. Structures of a ferrocenoyl-penicillin (1) and ferrocenyl-penicillin 2, and a ferrocenyl-
cephalosporin 3. 
 
 
Figure 4. Single crystal structures of two organometallic derivatives of quinolone antibiotics (left: 
norfloxacin, right: ofloxacin). 
 
N-Heterocyclic Carbene Complexes as antimicrobial agents. 
Silver and its salts have been used as antimicrobial agents since the 17th century.43, 44 Not elemental 
silver itself but the cationic form (Ag+) is the species responsible for the antibacterial activity of such 
compounds.44 Despite evidence showing that Ag+ has multiple targets (e.g. cell wall, enzyme and 
DNA/RNA), the mechanism of action of Ag+ is still not fully understood.17 The successive discovery of 
penicillin and other antibiotics after the 1940s has slowly suppressed their uses particularly for internal 
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use. However, there has been a renewed interest in the field of silver-based antimicrobials after 1965 
when resistant organisms such as P. aeruginisa and P. mirabilis have emerged.45  
The Youngs research group was the first to introduce N-heterocyclic carbenes (NHCs) as carrier 
ligands for Ag+ in 2004 for antibacterial application purposes.46 One representative example of such a 
class of compound is Silvamist (4, Figure 5), a caffeine derived Ag-NHC which exhibits excellent 
antibacterial activity against drug resistant pathogenic bacteria at low micromolar concentration.17, 47-49  
Ag-NHCs were also shown to exhibit activity against pathogens causing cystic fibrosis in vitro as well 
as in vivo.32, 48-50 Worthy of note, recent publications by Roland, Tacke et al. described the antibacterial 
and cytotoxicity activities of several symmetrical and unsymmetrical new Ag-NHC complexes.51-53 
Although most of them have a promising antibacterial activity profile against Gram-positive as well as 
Gram-negative pathogens, they however suffer from the fact that they are also cytotoxic against 
mammalian cells. Since the advances in research on antimicrobial Ag-NHC complexes have been 
reviewed recently, we direct the readers to these articles for more details on this topic.17, 44, 50, 54, 55  
Compared to silver, much less attention has been paid to the development of other metal-NHC 
complexes as antibacterial agents. 50, 55 In 2004, Cetinkaya et al. studied the antibacterial activity of six 
cationic gold-NHC complexes.56 Different N-substituted imidazoles were used as carbene precursors to 
prepare the Au-NHC complexes. Among all, compounds 6, 7 and 8 (Figure 5) were found to have good 
antibacterial activity in vitro against a series of bacterial strains at minimum inhibitory concentrations 
(MIC) of 3.1 - 6.3 µg/mL. Shortly after, Ghosh and co-workers reported [1-benzyl-3-tert-
butylimidazol-2-ylidene]AuCl (10, Figure 5) which inhibits the growth of Gram-positive B. subtilis at a 
MIC of 15 ± 2.3 µM.57 Interestingly, 10 is ca. two times more potent than its Ag analogue 9 (Figure 5). 
Very recently, the antibacterial activity of a few other Au-NHC complexes with different N-
substituents on the benzimidazole and bis(iminoacenaphthene) (BIAN) scaffold was reported.58, 59 
However, all of them exhibited poor antibacterial activity. For more information on the subject, we 
invite the readers to consult the review article by Youngs and co-workers.50 
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Figure 5. Structures of several potent antimicrobial Ag- and Au-NHC complexes. 
 
Organometallic Derivatives of Platensimycin. 
The recent discovery of the naturally occurring bacterial fatty acid biosynthesis inhibitor, namely, 
platensimycin (11, Figure 6) is a breakthrough in antibiotic research.60 11 displays potent antibacterial 
activity against the Gram-positive pathogens such as Methicillin-resistant S. aureus (MRSA) or 
Vancomycin resistant E. faecalis at minimum inhibitory concentration (MIC) 0.5-2 µg/mL. It 
selectively inhibits one of the important enzymes, namely FabF in bacterial fatty acid biosynthesis. 
Indeed, 11 was co-crystallized with its target enzyme (a and b, Figure 8, from PDB code 2gfx).60 The 
polar benzoic acid unit is buried deep in the malonyl binding pocket while the lipophilic tetracyclic 
cage is placed into the mouth of the enzyme pocket (b, Figure 8). Following the identification of this 
lead structure, chemical synthesis efforts were undertaken to provide numerous chemically modified 
derivatives for structure activity relationship  (SAR) studies.61‐64 Concurrently with the emergence of 
purely organic derivatives of 11, our group embarked on a project to investigate the possibility of 
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replacing parts of this complicated organic molecule by organometallic groups (see Figure 6 for the 
design). Our hypothesis was to provide organometallic derivatives of 11, which would be synthetically 
easily accessible and, at the same time, would exhibit potent antibacterial activity. Moreover, a metal 
specific mode of action was expected from the organometallic derivatives. Various structurally diverse 
and stable metallocenes were employed for this purpose to provide four different types of achiral and 
chiral bioorganometallics (see Figure 7 for the structures).  
O
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Figure 6. Design of organometallic derivatives of platensimycin (11). 
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Figure 7. Structural overview of various organometallic derivatives of 11. 
Achiral organometallic derivatives of type A were obtained by replacing the tetracyclic cage with (η5/6-
arene)M(CO)3 (arene = C6Me5, C6H5, C5H4 and M = Cr, Mn) metal half sandwich moieties.65, 66 As 
shown in Figure 8 (c), docking experiment with 12 showed that the organometallic moiety fits nicely 
into the active site of the FabF enzyme. Among all type A derivatives, only the (η6-C6Me5)Cr(CO)3 
containing derivative 12 inhibited the Gram-positive B. subtilis growth at a MIC of 80 µg/mL. The 
activity is moderate compared to its parent compound platensimycin (MIC = 0.2 µg/mL against B. 
subtilis). Interestingly, the analogous (η6-C6H5)Cr(CO)3 containing derivative 13 did not exhibit any 
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antibacterial activity. This finding was correlated to the poor cellular uptake of 13 compared to 12 as 
confirmed by measuring the Cr-content inside the bacteria by ASS after treatment of B. subtilis cells 
with these compounds. In order to investigate whether 12 inhibits the bacterial fatty acid biosynthesis 
or has another mechanism of action, Bandow and co-workers studied the proteomic signature of B. 
subtilis after treatment with compound 12.67 As shown in Figure 9, the proteomic responses to 11 and 
12 were compared as the former induced exclusively the proteins belonging to the fatty acid 
biosynthesis inhibition signature. Neither the six signature markers nor any of the compound-specific 
marker proteins was induced by 12, indicating that it does not inhibit fatty acid biosynthesis. However, 
at least seventeen proteins were significantly upregulated upon treatment with 12. The comparison of 
the proteomic response to 12 with the proteomic profiles in the reference compendium68 did not yield a 
close match, although some of the marker proteins are also induced by membrane-active antibiotics. 
Furthermore, in contrast to 11 which is only bacteriostatic, compound 12 was found to be bacteriolytic 
at higher doses. This means that compound 12 not only inhibits bacterial growth, but destroys the 
bacteria by lysis. In summary, in this case, organometallic derivatization has changed the mechanism of 
action completely; the compound no longer inhibits the FabF enzyme but exhibits a multi-causal death 
effect. This unexpected new mode of action is important as the medicinal usefulness of fatty acid 
biosynthesis inhibitors has been questioned.69 
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Figure 8: Binding of platensimycin with FabF enzyme (a; cartoon and b; surface, PDB code 2gfx) and 
surface models of the manual docking of bioorganometallics 12 (c), 23 (d), 22 (e) and 24 (f) into the 
FabF enzyme pocket.65, 66, 70  Bioorganometallics and platensimycin are presented in orange and green, 
respectively. 
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Figure 9: The protein expression profiles of B. subtilis to treatment with 5 µg/mL platensimycin (A) 
and 25 µg/mL 12 (B) do not share marker proteins. Marker proteins are indicated by arrowheads. 
Boxes in (B) indicate the locations of fatty acid biosynthesis marker proteins. Pulse-labeled cytosolic 
proteins were separated by 2D-PAGE. Red false-color images representing protein biosynthesis after 
antibiotic treatment were warped onto green false-color images showing protein synthesis under control 
conditions. Antibiotic induced proteins appear red, repressed proteins green, and proteins synthesized 
at equal rates under both conditions appear yellow.67 Reproduced with permission of the publisher from 
reference.67 
As mentioned in the introduction, there has been a resurgence of interest in the derivatization of 
existing drugs with ferrocene, mainly in anticancer and antimalarial research.15, 21, 71-73 With this in 
mind, we designed achiral derivatives of type B, where ferrocene was employed as surrogate for the 
tetracyclic cage of 11 (see Figure 7).74 Moreover, we incorporated an acyclic keto group in the C5 
position that is absent in type A derivatives. The C5 keto group was assumed to serve a similar purpose 
as the cyclic keto group in the tetracyclic cage of 11 that forms a strong H-bond with the Ala309 
residue while bound to FabF enzyme (a and b, Figure 8).60, 74 Among the compounds 16-19, only 17 
containing a 1,3-di keto functionality showed weak antibacterial activity (MIC of 128 μg/mL) against 
Gram-positive S. aureus Mu50 (VISA). 
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Chirality often plays an important role in the biological activity of drugs. After getting two moderately 
active compounds (12 and 17) in the preliminary stage of this project, we extended our concept one 
step further by introducing chirality into the design of the next generation of bioorganometallic 
platensimycin analogues. Various metallocene-fused cyclohexanone moieties were employed as a 
surrogate for the tetracyclic cage of 11 (see Figure 7). These chiral derivatives are structurally even 
more similar to 11 compared to the achiral analogues. Both diastereomers of a C8-C9 (η6-
benzene)Cr(CO)3 fused derivative (20 and 21, Figure 7) of 11, abbreviated as type C, were 
synthesized.75 Unfortunately, both compounds 20 and 21 failed to exhibit any antibacterial activity. 
However, during the synthesis of these compounds, we had the opportunity of exploring various 
reactivity aspects associated with (η6-2-tetralone)Cr(CO)3 moiety. Analysis of the surface model of the 
crystal structure of 11 bound FabF enzyme showed the existence of a pocket for the C6-C7 fused 
cage.60 This observation led us to design C6-C7 organometallic fused derivatives of 11.66, 70 All these 
type D analogues are chiral molecules like type C and contain various metallocene moieties, however, 
not fused in the C8-C9 position (like 20 and 21, Figure 3), but fused in the C6-C7 position of the 
cyclohexanone ring. All previously reported bioactive purely organic analogues of 11 mainly focused 
on the modification of the C8-C9 fused tetracyclic cage. In contrast, type D derivatives represent a 
completely new class of analogues of 11 with C6-C7 substitution pattern. The rationale behind this 
design concept was verified by manual computer docking experiments of both metallocene-fused 
analogues 22 and 24, respectively (e and f, Figure 8). The metallocene moieties fit nicely in the active 
site when superimposed manually on 11 bound to its target enzyme FabF.60 The C6-C7 fused 
ferrocene/cymantrene occupies a pocket similarly to the C8-C9 fused tetracyclic cage of 11 and the 
keto carbonyl oxygen is capable of forming an H-bond with Ala309. The [3]-ferrocenophane-1-one 
based derivative 23 also showed similar result (d, Figure 8). We therefore expected that this new 
substitution pattern would provide crucial information on the effect of steric bulk fused at C6-C7 
position instead of C8-C9 position on the biological activity of 11. The organometallic compounds 
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employed were (η6-benzene)Cr(CO)3, ferrocene and cymantrene for the type D analogues. The size of 
the organometallic moieties increases in the order ferrocene < cymantrene < (η6-benzene)Cr(CO)3. 
Despite both 22 and 23 containing ferrocene, they still possess significant structural differences. While 
22 consists of a homo-annular ferrocene moiety, the [3]-ferrocenophane-1-one based derivative 23 
contains a hetero-annular C3 bridged ferrocene moiety which is slightly strained. Although the manual 
docking showed the newly designed organometallic analogues fit into the active site of FabF, the 
compounds did not exhibit any antibacterial activity against either Gram-positive or Gram-negative 
bacterial strains. The lack of activity is perhaps due to insufficient cell permeability of the 
bioorganometallic compounds as recently demonstrated for several other synthetic and natural purely 
organic congeners of 11 having a modified tetracyclic cage.63, 64  
Conclusions. 
Over the last years, research in medicinal organometallic chemistry has mainly focused on the 
preparation of organometallic compounds for anticancer and antimalarial purposes. Despite stunning 
results, it is surprising that organometallic compounds have not received more attention as 
antimicrobial agents, especially considering that the first, and probably the most prominent 
organometallic complex to date, namely Salvarsan®, was an anti-infective drug! Taking into account 
the urgent need for novel antibiotics, we strongly believe that more organometallic compounds deserve 
to be tested for antimicrobial purposes in the very near future, and their mechanism of action be 
investigated. Clearly, metal complexes have the potential for completely new, metal-specific modes of 
action that may make it difficult for bacteria to develop mechanisms of resistance. 
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